Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

To join this study, you need to be an adult between 40 and 80 years old. You must have been diagnosed with moderate to severe COPD for at least a year, and your current inhaler treatments shouldn't be fully controlling your symptoms. This means you should have experienced frequent flare-ups in the past year. Also, blood tests will show a specific type of inflammation in your body. You should be taking a combination of three types of inhaler medicines for at least six months before starting the study.

There are also some reasons why you might not be able to join. For example, if you've ever been diagnosed with asthma, or if your doctor thinks another lung condition is causing most of your breathing problems. You also can't have had pneumonia, a COPD flare-up, or a chest infection in the four weeks before starting the study. Certain lung surgeries or being in the middle of an intensive lung rehabilitation program would also mean you couldn't take part.

If you decide to take part, you'll be given either the study medicine (depemokimab) or a placebo, which looks identical but has no active drug. You won't know which one you're receiving, nor will your study doctor. This is called a 'blinded' study, which helps make sure the results are fair. You'll continue using your regular inhalers throughout the study.

You'll need to attend several visits to the study clinic. These visits will involve health checks, breathing tests, blood tests, and discussions about your symptoms and how you're feeling. The study team will provide you with the study medicine. The total duration of your participation will be explained by the study team, but it's typically for an extended period to properly assess the medicine's effects. Regular follow-up appointments will be scheduled to monitor your health and any effects of the medicine.